Humana (NYSE:HUM – Free Report) had its price target reduced by Truist Financial from $400.00 to $260.00 in a research report report published on Friday morning, Benzinga reports. They currently have a hold rating on the insurance provider’s stock.
Other equities research analysts have also recently issued research reports about the company. Morgan Stanley initiated coverage on Humana in a research note on Monday, June 24th. They issued an equal weight rating and a $374.00 price target for the company. Jefferies Financial Group cut Humana from a buy rating to a hold rating and lowered their price target for the company from $519.00 to $253.00 in a research note on Monday, October 7th. KeyCorp assumed coverage on Humana in a report on Friday. They issued a sector weight rating for the company. Oppenheimer reduced their target price on Humana from $400.00 to $280.00 and set an outperform rating for the company in a report on Thursday, October 3rd. Finally, Bank of America lowered Humana from a neutral rating to an underperform rating and reduced their target price for the stock from $376.00 to $247.00 in a report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Humana presently has a consensus rating of Hold and an average target price of $315.33.
Get Our Latest Analysis on HUM
Humana Trading Up 3.7 %
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.94 EPS. On average, research analysts predict that Humana will post 16.06 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.32%. Humana’s payout ratio is 22.04%.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Heritage Oak Wealth Advisors LLC acquired a new position in shares of Humana in the second quarter valued at $3,456,000. APG Asset Management US Inc. raised its stake in shares of Humana by 3.0% in the second quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after purchasing an additional 1,955 shares in the last quarter. Sei Investments Co. raised its stake in shares of Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after purchasing an additional 264 shares in the last quarter. Cetera Advisors LLC grew its position in Humana by 472.1% in the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock valued at $3,501,000 after acquiring an additional 8,333 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in Humana by 113.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,619 shares of the insurance provider’s stock valued at $2,099,000 after acquiring an additional 2,986 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
- Five stocks we like better than Humana
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- What is the Shanghai Stock Exchange Composite Index?
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- What Are the U.K. Market Holidays? How to Invest and Trade
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.